Market Place
Sourcing Support
All News #Library
Biotech
FDA Accepts BLA for Duchenne Muscular Dystrophy Cardiomyopathy Treatment
11 Mar 2025 //
PR NEWSWIRE
Ns Pharma Viltolarsen Phase 3: Racer53 Preliminary Results Shared
27 May 2024 //
PR NEWSWIRE
NS-089/NCNP-02 Receives ODD from EC for Duchenne Muscular Dystrophy
21 Dec 2023 //
PR NEWSWIRE
NS-089/NCNP-02 Preclinical Data Published in Molecular Therapy Nucleic Acids
17 Oct 2023 //
PR NEWSWIRE
NS Pharma Announces FDA Clearance to Initiate a PhI/II Study for NS-050/NCNP-03
15 Jun 2023 //
PR NEWSWIRE
VILTEPSO® (viltolarsen) injection Four-Year Clinical Trial Data Published
09 May 2023 //
PR NEWSWIRE
NS Pharma Announces FDA Clearance to Initiate Phase II Study for NS-089/NCNP-02
14 Apr 2023 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.